Xencor reported $-28000000 in EBIT for its second fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Ebit Change
Alnylam Pharmaceuticals ALNY:US $ -191686000 44.95M
Amgen AMGN:US $ 2176M 324M
Arrowhead Research ARWR:US $ -72909000 114.46M
AstraZeneca AZN:LN 181.11B 36.36B
Biogen BIIB:US $ 940.9M 409.4M
Bristol Myers Squibb BMY:US $ 3197M 9M
Cytokinetics CYTK:US $ -10874000 66.98M
Epizyme EPZM:US $ -29806000 21.12M
GlaxoSmithKline GSK:LN 181.6B 5.9B
Johnson & Johnson JNJ:US $ 6941M 599M
Karyopharm Therapeutics KPTI:US $ -42908000 8.32M
Macrogenics MGNX:US $ -41808000 24.83M
Merk MRK:US $ 5711M 652M
Novartis NOVN:VX 3.32B 176M
Pfizer PFE:US $ 12099M 2104M
Regeneron Pharmaceuticals REGN:US $ 1306.9M 20.3M
Seattle Genetics SGEN:US $ -133111000 61K
Xencor XNCR:US $ -28000000 54.47M